XML 73 R61.htm IDEA: XBRL DOCUMENT v3.25.3
Segment Information - Schedule of Financial Information (Details) - USD ($)
$ in Thousands
 1 Months Ended 3 Months Ended 9 Months Ended
Jan. 31, 2025
Sep. 30, 2025
Sep. 30, 2024
Sep. 30, 2025
Sep. 30, 2024
Revenue, Major Customer [Line Items]          
Revenue   $ 0 $ 0 $ 70 $ 0
Operating Expenses:          
Research and development   1,959 2,542 6,815 8,384
Operating loss   (4,414) (5,336) (15,130) (17,460)
Other income, net   (18) (45) (129) (246)
Benefit from income taxes $ 962 0 0 (962) (798)
Net loss   (4,249) (4,930) (13,632) (15,375)
Reportable Segment          
Operating Expenses:          
Research and development   1,959 2,542 6,815 8,384
General and administrative   2,455 2,794 8,385 9,076
Investor relations/public relations/communications   306 338 946 969
Finance   539 562 1,706 1,727
Legal   183 174 734 1,084
Business development   134 120 401 437
Share based compensation expense   195 292 811 860
Other   30 125 417 412
Operating loss   (4,414) (5,336) (15,130) (17,460)
Other income, net   165 406 536 1,287
Benefit from income taxes   0 0 (962) (798)
Net loss   (4,249) (4,930) (13,632) (15,375)
Cash, cash equivalents, and marketable securities   18,998 35,856 18,998 35,856
Reportable Segment | Segment Reporting, Reconciling Item, Corporate Nonsegment          
Operating Expenses:          
General and administrative   1,068 1,183 3,370 3,587
Reportable Segment | BOLSTER trial          
Operating Expenses:          
Research and development   829 475 2,222 2,820
Reportable Segment | ASCEND trial          
Operating Expenses:          
Research and development   8 133 61 271
Reportable Segment | Chemistry, manufacturing and controls          
Operating Expenses:          
Research and development   157 764 543 1,703
Reportable Segment | Clinical department          
Operating Expenses:          
Research and development   654 1,001 2,802 3,191
Reportable Segment | Other          
Operating Expenses:          
Research and development   $ 311 $ 169 $ 1,187 $ 399